A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas.
Phase of Trial: Phase 0
Latest Information Update: 12 Jul 2017
At a glance
- Drugs SL 701 (Primary) ; Poly ICLC
- Indications Astrocytoma; Oligodendroglioma
- Focus Adverse reactions; Pharmacodynamics
- 14 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00795457).
- 10 Sep 2014 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record (NCT00795457).
- 06 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History